Spinal cord stimulators have grown in popularity over the past several years as patients see benefits in the less-invasive ...

Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have earned a consensus rating of “Reduce” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two investment ...

NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

Several spine and orthopedic companies have made progress with acquisitions in the first quarter of 2025. 1. Stryker has ...

PNC Financial Services Group Inc. lifted its position in Nevro Corp. (NYSE:NVRO – Free Report) by 62.3% during the fourth quarter, according to its most recent 13F filing with the Securities and ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

The global motion stimulation therapy market is set for significant growth, with market projections estimating its value at USD 1.4 billion in 2024. Fueled by rapid technological integration in ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...